Active ingredientLurbinectedinCat. No. P-L111-001CAS 497871-47-3Family · Pharmaceutical analytical standards
Lurbinectedin
An anticancer drug that binds DNA and blocks the transcription of genes many tumour cells depend on; it received accelerated approval in the United States in June 2020 for metastatic small cell lung cancer already treated with platinum-based chemotherapy. This family brings together the active ingredient and other impurities.
Did you know?It is a synthetic relative of trabectedin, discovered in the sea squirt Ecteinascidia turbinata, a small marine animal: obtaining a single gram of trabectedin would take about a tonne of sea squirts.
Go to the active ingredient →Active ingredientLurbinectedinCat. No. P-L111-001CAS 497871-47-3
ImpurityLurbinectedin Cyano ImpurityCat. No. P-L111-002CAS 497871-10-0
ImpurityLurbinectedin Deacylated ImpurityCat. No. P-L111-003CAS 3054883-63-2
ImpurityLurbinectedin Impurity 1Cat. No. P-L111-005
ImpurityLurbinectedin Impurity 2Cat. No. P-L111-006CAS 577748-36-8
ImpurityLurbinectedin Impurity 3Cat. No. P-L111-007
ImpurityLurbinectedin Impurity 4Cat. No. P-L111-009
ImpurityLurbinectedin Impurity 5Cat. No. P-L111-010
ImpurityLurbinectedin Impurity 6Cat. No. P-L111-011
ImpurityLurbinectedin Impurity 7Cat. No. P-L111-013
ImpurityLurbinectedin SulfoxideCat. No. P-L111-015No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.